about
Lung cancer-a fractal viewpoint.ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecanPaxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasionCarboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancerPilot study examining tumor expression of RAD51 and clinical outcomes in human head cancersProteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology databaseNivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung CancerAdjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancerValidation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups.Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.Phase I study of dose-dense alternating doublets in advanced non-small-cell lung cancer.Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck.A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma.Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430.A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104.Phase II study of sunitinib malate in head and neck squamous cell carcinoma.Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II studyChemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904.Differences in clinical trial patient attributes and outcomes according to enrollment setting.Induction chemotherapy for head and neck cancer: recent data.A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904.Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancerPhase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context.Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.
P50
Q27310294-32B67E4E-82F2-428A-B824-64D7DE95D9DCQ27928062-807455C8-A9F7-499B-8794-6E9A7C5E3F31Q28249001-3B331EC8-8D6A-4B45-A92E-B8DD732AE738Q28263339-61C54986-76C1-42D1-828A-B9D01A158E67Q28265589-B1AC0D8C-5952-4D16-ADA2-B2ACF58AEA69Q28305880-E70A6D18-F8B7-4D16-8910-6AAC83EB1557Q28391454-35FE4D6D-08C4-4D4F-BB41-0340F9F040B5Q29620913-CED09380-F60C-4C91-B24B-EA1DD8308AA1Q30438068-F1EC784E-7B66-4909-9A77-615BA9D511F6Q30494514-805FC0DA-E670-4B8E-9BBA-A9172FCE60D7Q30542819-14BFAD40-C57F-436B-B93B-B40883D40175Q30670518-E0965F55-8558-479D-B47A-0D8A5DEEAB05Q31154012-BAD1FA1E-4C8C-4CCB-BA82-095E08707DD0Q33153624-9776D1E9-E912-4039-99F1-06CCA6099A48Q33344687-41F95643-BED8-480C-A455-0BB4D5AECC1AQ33357974-D41EF8A2-2166-4A1C-BAA7-F76F0AB4F860Q33358394-5FC9B5CC-2AA6-434B-93A7-134D5B995FE9Q33362039-893BD7F0-1659-456F-BCAC-95DBF6A02D71Q33370457-540035F5-6DD6-433E-B041-6D65C6779B88Q33375762-DDA4C6C8-50BB-4D99-85C6-FA7999885E52Q33381874-B57AFA61-2DB6-40B9-BEBE-790003955F29Q33382993-57BCE1D2-0E38-4D2B-803C-586E9CE89947Q33385634-BB490140-9F88-44FF-A0D7-8E910C6E7F25Q33392042-B4DC12E9-B374-4AD7-B72A-7BF9F7BBA452Q33397464-2C956EAA-E037-40CF-B2D5-E8EA740033A4Q33406802-5DCD56E9-6D94-4821-9580-6924FE98F95FQ33420821-65483A52-906C-4B09-9B7C-6CD288BB7576Q33439007-78323588-9C80-4CAD-ACB3-A4C77B1BAD1EQ33528991-03D42491-ACDC-473D-AD54-8729B86CBCFCQ33627751-55ED3969-232F-4358-9FA4-238FC219F395Q33627769-D80962B5-5B9D-4C5B-A274-39B7E4D2FF1DQ33734261-B608E106-2EF0-4CE0-AC7E-FE5C81E70D66Q33742211-AF91010C-487C-4152-9415-3009834D7086Q33785927-95904F03-3130-4BA3-AA3F-32E92CEDB5B7Q33816617-F7F763C6-065C-4E36-B6EC-F2446A470114Q33902741-DC608728-82E2-4D7C-829A-01061171358CQ33990915-6F169CB3-462A-4D13-829D-001CBEA2E1C2Q34026037-56C2894D-6B16-4A78-BB58-7F0B76630932Q34192330-B8A2DCB4-F4F1-4E9C-9E6C-1EABFE33A7D7Q34287207-E0CE7B5B-8BD9-438D-BE70-7081ACF2CB03
P50
name
Everett E Vokes
@en
Everett E Vokes
@nl
type
label
Everett E Vokes
@en
Everett E Vokes
@nl
prefLabel
Everett E Vokes
@en
Everett E Vokes
@nl